42 results about "During menopause" patented technology

The invention discloses application of PGRN in preparation of products for preventing and treating neuropsychiatric disorder related diseases caused by estrogen deficiency. The invention provides an application of a PGRN protein or a coding gene thereof or a virus expressing the coding gene thereof in preparation of a product with any one of the following functions: 1) preventing or treating or saving neuropsychiatric disorder related diseases caused by estrogen deficiency; 2) preventing or treating perimenopausal anxiety and / or depression symptoms; and 3) relieving anxiety-like behaviors and / or depression-like behaviors caused by estrogen deficiency. The application proves that the PGRN can play a role in protecting neuron damage caused by estrogen deficiency by rescuing CTSD enzyme activity and an autophagy pathway, and prompts that related medicines and measures influencing secretion and content of the PGRN can treat perimenopausal anxiety and depressive symptoms; and a new target and a new idea are provided for clinical treatment and drug development of anxiety and depression symptoms of climacteric women.

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

The present invention relates to an oral extract composition comprising Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) extract composition, and its process of preparation. Also relates to the oral extract composition formulation comprising with synergistic combinations of the Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) in suitable doses and at least one nutraceutically and / or pharmaceutically accepted excipient for, improvement, and maintenance of women health more preferably in improving of hot flashes, night sweats, poor sleep, anxiety, sexual dysfunction, mood changes, Genitourinary symptoms in overall improving the quality of life, serum estradiol, progesterone, follicle stimulating hormone (FSH), and cortisol during the period of menopause (perimenopause and menopause). The oral extract composition formulation comprising with synergistic combinations of the Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) in suitable doses and at least one nutraceutically and / or pharmaceutically accepted excipient is used for improving Brain-derived neurotrophic factor (BDNF) levels in women during the period of menopause. The present invention, further related to the extraction process of Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.), also provides the process for the preparation of formulation composition. This invention further relates to the extraction process from Shatavari (Asparagus racemosus Willd.) and Fenugreek (Trigonella foenum-graecum L.) either as individual herbs or co-extraction of the two herbs or mixing the extracts at various stages of the individual extracts.

Provided herein are methods of treating symptoms associated with menopause, perimenopause and / or post-menopause in a subject in need thereof by administering to the subject compositions comprising a triple reuptake inhibitor (e.g., Compound 1).

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

The invention relates to the technical field of traditional Chinese medicines, and discloses a classic prescription for treating hypoovarian reserve function, which is prepared from the following raw materials: 30 to 40g of Chinese yam, 20 to 30g of semen cuscutae, 10 to 20g of fructus lycii, 10 to 15g of radix achyranthis bidentatae, 10 to 20g of codonopsis pilosula, 10 to 20g of poria cocos, 20 to 30g of malt, 10 to 15g of angelica sinensis and 10 to 30g of radix puerariae. The classical prescription for treating the hypoovarian reserve function has a positive curative effect, and modern network pharmacology also scientifically proves that active ingredients such as quercetin, daidzein, kaempferol and the like contained in the kidney-tonifying and menstruation-regulating prescription are flavonoid compounds from the aspect of action mechanism, so that the prescription has very good anti-inflammatory and anti-oxidative stress ovarian protection effects; the application range is wide, clinical manifestations of patients with the ovarian reserve function decline are generally hypomenorrhea, menoxenia, amenorrhea, infertility or perimenopausal symptoms, and the kidney tonifying and menstruation regulating prescription has a certain regulating effect on the hypomenorrhea.

The invention relates to the technical field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for treating perimenopausal syndrome, which is composed of podophyllum hexandrum, lagotis, honeysuckle fruit, bamboo shavings, pilose antler and sea-buckthorn. The composition takes podophyllum hexandrum as a monarch drug, sea-buckthorn and honeysuckle fruit as ministerial drugs to enhance the effects of promoting blood circulation and regulating menstruation, cornu cervi pantotrichum for replenishing essence and blood, warming yang and dispelling cold, and bamboo shavings and lagotis herb as adjuvant drugs for cooling blood and clearing heat, so that a three-dimensional system of promoting blood circulation, tonifying and clearing heat is formed. It is verified that the composition can relieve uterine atrophy, improve organic decline of a reproductive system, reduce whole blood viscosity and abnormally-increased leukocyte number, inhibit inflammation, accurately adjust serum E2, LH, PROG and AMH levels so as to remodel hormone balance and avoid side effects of exogenous hormones. The composition is based on the advantages of Tibetan medicines and the multi-target effect of natural medicinal materials, conforms to the modern research and development trend and is high in clinical transformation value.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of a Dan'e Fukang preparation in preparation of a medicine for treating perimenopausal syndrome. The invention provides application of a Dan'e Fukang preparation in preparation of a medicine for treating perimenopausal syndrome. Pharmacological experiments prove that Dan'e Fukang can reduce the number of activities of mice and prolong the sleep time of the barbital sodium of the mice, and has certain sedative, hypnotic and anxiety-resistant effects; the composition can effectively resist rat foot plantar sweat secretion caused by pilocarpine, and has a certain effect of resisting sweating; moreover, the traditional Chinese medicine composition has an obvious effect of reducing LH, FSH and T in climacteric rats, has an effect of increasing E2 in serum of the climacteric rats, and can be used for effectively treating the perimenopausal syndrome. Dan'e'fukang can reduce the total accumulated immobility time of the rat in the forced swimming experiment; the despair state time of a tail suspension experiment rat is obviously shortened, and a certain anti-depression effect is achieved. The Dan'e Fukang can provide more drug choices for clinical treatment of perimenopausal syndrome diseases.

Embodiments of the invention comprise a test strip configured to detect one or more metabolites of progesterone in urine, and optionally further detect one or more additional metabolites or hormones in urine within the same test strip. Embodiments of the invention are methods of utilizing such a test strip in association with avoidance of pregnancy, detection of menopause, and in association with fertility planning purposes. Embodiments of the invention are associated with the incorporation of a test strip within a testing kit, optionally further comprising a digital reader.

The invention discloses a composition for regulating female endocrine and a preparation method thereof. Belongs to the technical field of biological medicine. The invention aims to solve the defects of female endocrine dyscrasia in the prior art, including unstable curative effect, slow effect, inconvenience in taking and the like, through the synergistic effect of specific components and an optimized preparation process. According to the composition, a prepared rehmannia root extract, a coptis chinensis extract, a white peony root extract, a scutellaria baicalensis extract, donkey-hide gelatin and poria cocos are taken as main active ingredients, oryzanol, vitamin B6 and 7-methylisonorethindrone are taken as auxiliary ingredients, and comprehensive regulation on female endocrine systems with climacteric and menopausal syndromes is realized through a scientific proportion and a unique preparation process. The components in the traditional Chinese medicine composition have a synergistic effect and comprehensively and accurately regulate endocrine, the core traditional Chinese medicine extracts are complementary, the endocrine dyscrasia mechanism is improved in a targeted manner, and the curative effect stability is guaranteed through scientific proportioning; the extraction process is optimized, and the utilization rate and activity of effective components are improved; the product form and the taking mode are optimized, the user compliance is improved, the multi-scene requirement is met, and the industrial pain point is solved.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition and a preparation method and application thereof. Specifically, the traditional Chinese medicine composition is prepared from radix salviae miltiorrhizae, rhizoma coptidis, rhizoma anemarrhenae, radix ophiopogonis, nacre mother of pearl and semen ziziphi spinosae. The traditional Chinese medicine composition provided by the invention is simple in formula, does not contain precious, thin, toxic and endangered medicinal materials, and in a naturally aged female climacteric mouse model, the traditional Chinese medicine composition formula can obviously increase the level of E2 in plasma, lower the levels of FSH and LH and improve the pathological characteristics of uterus tissues. Test results show that the traditional Chinese medicine composition provided by the invention has a certain treatment effect on patients with perimenopausal syndromes.

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including in overweight or obese subjects. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation or symptoms of menopause, including in overweight or obese subjects.

Microemulsions are described where hydrophobic liquid droplets are distributed in a continuous hydrophilic liquid phase. In relation to conventional oil-in-water (OIW) microemulsions, the described microemulsions may be thought of as modified oil-in-water (MOIW) microemulsions, where both the “oil” and “water” phases of the microemulsion are modified. The oil phase droplets of the MOIW microemulsion are modified with alcohol and can solubilize alcohol-soluble species, including nonderivatized hormones. More preferably, the modified oil phase droplets of the MOIW microemulsion directly solubilize nonderivatized hormones. The oil phase droplets of the MOIW microemulsion include DHEA, pregnenolone, and a polyphenol, where a ratio of DHEA to polyphenol is from 1:1 to 12:1 by weight. Methods of supporting and / or increasing bloodstream hormone levels in perimenopausal and postmenopausal females and improving menopausal symptoms also are disclosed.

The invention discloses an application of a liver 20-HETE synthesis inhibitor in preparation of a medicine for treating perimenopausal mood disorder. According to the application, a perimenopausal mouse model is constructed through ovariectomy, a behavioral test observes that the perimenopausal mouse model shows obvious depression and anxiety behaviors, the expression of 20-HETE synthetase Cyp4a12a in the liver of the ovariectomy mouse model is obviously increased, and the level of 20-HETE in plasma is obviously increased; by using the liver 20-HETE synthetase inhibitor TS-011 for intervention, the content of 20-HETE in the plasma of the ovariectomy mouse is remarkably reduced, and the depression and anxiety-like behaviors of the mouse are remarkably improved. It is found that the liver 20-HETE synthesis inhibitor can be applied to development or preparation of perimenopausal mood disorder treatment drugs which are low in side effect and high in clinical acceptability, and the liver 20-HETE synthesis inhibitor has high clinical transformation value.

This invention provides a composition, an article comprising the same, and its application, relating to the field of dairy product technology. The composition provided by this invention comprises, by weight, the following components: 5-8 parts black cohosh extract, 0.5-2.5 parts banana flower extract, and 1.5-2.5 parts rice bran oil extract. In this composition, the black cohosh extract, rice bran oil extract, and banana flower extract work synergistically to maintain a good balance in bone calcium absorption and metabolism, significantly improving bone density, and is particularly applicable to improving bone density in middle-aged and elderly individuals and postmenopausal women.

Methods and compositions increase iron absorption, for example by increasing iron absorbability and / or increasing iron bioavailability. A method for increasing iron absorption, preferably naturally present in plant-based food, meal or diet, includes administering to an individual in need thereof a milk-based composition galactooligosaccharide (GOS), preferably a low sugar low lactose milk composition comprising galactooligosaccharide (GOS). The individual, to whom the milk-based composition is administered, may be chosen from adults; older adults; pregnant or lactating women; menopausal or perimenopausal women, infants; children; and subjects consuming a vegetarian diet, a flexitarian diet, a vegan diet or any type of plant-based diet.

The application discloses application of a liver 20-HETE synthesis inhibitor in preparation of a medicine for treating perimenstrual mood disorders. The application constructs a perimenstrual mouse model through ovariectomy, and it is observed through behavior test that the perimenstrual model mouse shows obvious depressive and anxious behaviors. The expression of 20-HETE synthesis enzyme Cyp4a12a in the liver of the ovariectomy model mouse is significantly increased, and the 20-HETE level in the plasma is significantly increased. Through intervention by using a liver 20-HETE synthesis enzyme inhibitor TS-011, the 20-HETE content in the plasma of the ovariectomy mouse is significantly reduced, and the depressive and anxious behaviors of the mouse are obviously improved. It is found by the application that the liver 20-HETE synthesis inhibitor can be applied to development or preparation of a perimenstrual mood disorder treatment medicine with low side effects and high clinical acceptance, and has high clinical transformation value.

Methods, uses and products including a recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylation and menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age≥35 are described.

The application relates to a traditional Chinese medicine composition for nourishing kidney and relieving depression as well as a preparation method and application thereof. The application relates to a traditional Chinese medicine composition and a preparation method and application thereof. In order to solve the problems that long-term hormone replacement therapy not only has more adverse reactions, but also has potential risks of causing endometrial lesions, thrombosis and tumors, the traditional Chinese medicine composition comprises radix codonopsis, radix ophiopogonis, taxilli herba, radix dioscoreae, ligustri fructus, anemarrhena asphodeloides, herba ecliptae, radix paeoniae alba, radix bupleuri, pericarpium citri reticulatae, fritillaria, poria cocos, semen ziziphi spinosae and schisandra chinensis. The traditional Chinese medicine composition is applied to preparation of a medicine for preventing and / or treating perimenopausal syndrome and premature ovarian failure. The application belongs to the technical field of medicines.

The invention relates to the field of pharmaceutical preparations, in particular to an epimedin C liposome as well as a preparation method and application thereof. The epimedin C liposome provided by the invention is prepared from epimedin C, phospholipid, steroid and a nonionic emulsifier. The invention also provides a preparation method and application of the epimedin C liposome. The epimedin C lipidosome prepared by the invention has good stability and high drug encapsulation efficiency, and experimental results show that the lipidosome can promote the generation of endogenous estradiol in a low-estrogen environment by activating aromatase, so that the development of a new dosage form of the lipidosome can reduce the administration frequency and improve the bioavailability. The traditional Chinese medicine composition can be used for preventing or delaying the perimenopausal syndrome and perimenopausal related diseases, and meanwhile, an effective and convenient treatment scheme is provided for ovarian failure or estrogen deficiency caused by bilateral ovariectomy.

The invention discloses a preparation method and application of a medicine for preventing and treating premature ovarian failure, the medicine comprises the following components in parts by weight: 3-10 parts of eucommia ulmoides, 2-8 parts of salvia miltiorrhiza and 1-6 parts of ligusticum wallichii. The premature ovarian failure (POF) is also called ovarian insufficiency, refers to ovarian function decline, follicle-stimulating hormone level increase and estrogen level decrease of women before 40 years old, and shows secondary amenorrhea and infertility, and is often accompanied with menopausal symptoms such as sweating, insomnia, hypomnesis and the like in a night sleep process; at present, hormone replacement treatment is a main treatment method for premature ovarian failure, but the side effect is large after hormone is taken for a long time, and the probability of suffering from breast cancer and endometrial cancer can be increased; the medicine composition disclosed by the invention can be further developed into a molecular traditional Chinese medicine for preventing POF and delaying the POF process, so that the comprehensive utilization of the composition is promoted, and a new choice is provided for patients with POF.

The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component.The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.

The present invention discloses a probiotic composition for improving menopausal symptoms and its application, which combines raw materials of both medicine and food with probiotics complementing each other, having a simple composition and synergistic effect, being rich in various essential nutrients and trace elements for the human body, and having the functions of strengthening the spleen and stomach, nourishing the liver and kidney, and calming the nerves, and can improve symptoms such as hot flashes and sweating, insomnia and dreaminess during menopause. The present invention can be used to improve menopausal syndrome, expanding the application field of probiotics.

The present invention relates to a hormone replacement therapy, to the associated compounds and to the associated packaging units, for alleviating menopause-associated symptoms which is based on the administration to a female mammal of an estetrol component at specified daily doses, optionally in combination with a progestogenic component.The therapy enjoys a statistically significant efficacy combined with a favourable profile for side effects compared to currently available methods for alleviating menopause-associated symptoms.

The disclosure provides methods of reducing or eliminating the need for ovarian function suppression (OFS) in a premenopausal or perimenopausal female patient with hormone receptor-positive (HR+) breast cancer. The method comprises the administration of an effective amount of lasofoxifene, or a pharmaceutically acceptable salt or a functional derivative thereof in neoadjuvant and adjuvant treatment.

The invention discloses a culture solution and a method for improving in-vitro maturation and quality of remaining GV stage ova after ICSI, and relates to the field of assisted reproduction. The invention provides a culture solution for improving in-vitro maturation and quality of remaining GV stage ova after ICSI, the culture solution is a BM-CoE finished product culture solution composed of 50 [mu] M of coenzyme Q10, 10 ng / ml of epidermal growth factors and a BM basic culture solution, and the BM basic culture solution is composed of a finished product blastocyst culture solution 1029, a 10% serum protein substitute, 29 [mu] M of sodium pyruvate and 1.5 IU / ml of human menopausal gonadotropin. By jointly adding the coenzyme Q10 and the epidermal growth factor with certain concentration into the BM basic culture solution, compared with a commercially available finished product oocyte in-vitro maturation culture solution, the culture solution disclosed by the invention not only can obtain higher oocyte maturation rate and better mature oocyte quality, but also is beneficial to improving the clinical oocyte utilization rate and increasing the number of available embryos of a patient.

The invention provides application of oviductus ranae in preparation of drugs for preventing and / or treating perimenopausal depression, and particularly belongs to the technical field of drugs for perimenopausal depression. The invention provides application of oviductus ranae in preparation of a medicine for preventing and / or treating perimenopausal depression. The oviductus ranae can remarkably improve depression-like behaviors of mice with perimenopausal depression and has the effect of treating the perimenopausal depression. Specifically, the oviductus ranae can increase sucrose intake of mice with perimenopausal depression, improve social behaviors, increase exploration desire, repair neuron damage, reduce the levels of FSH, LH and CORT in serum, up-regulate the content of 5-HT and 5-HIAA neurotransmitters and improve the expression level of brain neurotrophic factors BDNF and estrogen receptor ERalpha and ERbeta proteins, and has the effect of regulating and controlling PI3K / AKT signal channels.

The present invention relates to a composition comprising an estetrol component for use in alleviating estrogen deficiency symptoms, including menopausal related symptoms, in a subject characterized by a degree of liver injury. The compositions described herein exhibit advantageous pharmacokinetic properties when compared to existing estrogen-based compositions intended to alleviate symptoms of estrogen deficiency. Uses related to the above and corresponding methods of treatment are also described herein.

The disclosure provides methods of reducing or eliminating the need for ovarian function suppression (OFS) in a premenopausal or perimenopausal female patient with hormone receptor-positive (HR+) breast cancer. The method comprises the administration of an effective amount of lasofoxifene, or a pharmaceutically acceptable salt or a functional derivative thereof in neoadjuvant and adjuvant treatment.